Postmenopause Symptoms: Drugs That Cause or Treat Them

What Counts as a Postmenopausal Symptom

Postmenopause begins 12 months after a woman's final menstrual period. Symptoms cluster into vasomotor (hot flashes, night sweats), genitourinary (vaginal dryness, dyspareunia, urinary urgency), neuropsychiatric (insomnia, mood lability, cognitive fog), and musculoskeletal (joint stiffness, accelerated bone loss) domains.

The Study of Women's Health Across the Nation (SWAN) followed 1,449 women longitudinally and found that the median total duration of frequent vasomotor symptoms was 7.4 years, with a median persistence of 4.5 years after the final menstrual period [1]. Women who entered menopause earlier or who were Black or Hispanic experienced longer symptom duration. This is not a brief transition. For many women, a decade of clinically significant symptoms is the norm, and pharmacologic management becomes a practical necessity rather than a convenience.

Genitourinary syndrome of menopause (GSM) is progressive. Unlike hot flashes, which may eventually remit, vaginal atrophy worsens without intervention [2]. The North American Menopause Society (NAMS) 2020 position statement confirms that GSM affects up to 84% of postmenopausal women and does not resolve spontaneously.

Drugs That Treat Postmenopausal Vasomotor Symptoms

Systemic hormone therapy remains the most effective pharmacologic intervention for hot flashes. Conjugated equine estrogens (CEE) 0.625 mg/day or 17β-estradiol 1 mg/day reduce hot flash frequency by 75% compared with approximately 50% for placebo in pooled trial data [3].

For women with an intact uterus, a progestogen (medroxyprogesterone acetate 2.5 mg/day or micronized progesterone 100 mg/day) is co-prescribed to prevent endometrial hyperplasia. The 2022 NAMS position statement reaffirms that for women under 60, or within 10 years of menopause onset, the benefits of hormone therapy outweigh risks for most [4].

Non-hormonal alternatives now include fezolinetant (Veozah), a neurokinin 3 (NK3) receptor antagonist approved by the FDA in May 2023. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg/day reduced moderate-to-severe vasomotor symptom frequency by 61.3% at week 12 versus 42.4% for placebo [5]. The drug blocks the hypothalamic KNDy neuron pathway that drives thermoregulatory dysfunction after estrogen withdrawal.

Paroxetine 7.5 mg (Brisdelle) remains the only SSRI with a specific FDA indication for vasomotor symptoms. Its approval was based on two trials totaling 1,175 women showing a reduction of 1.66 hot flashes per day versus 1.02 for placebo at 12 weeks [6]. Gabapentin 900 mg/day and clonidine 0.1 mg/day are used off-label but produce smaller effect sizes and more side effects (dizziness, dry mouth, somnolence).

Oxybutynin 2.5 mg twice daily showed a 77% reduction in hot flash bother scores in a randomized trial (N=150), offering an unexpected option for women who cannot take hormones [7].

Drugs That Treat Genitourinary Syndrome of Menopause

Low-dose vaginal estrogen is first-line for GSM. A Cochrane review of 30 trials (N=6,235) found that vaginal estrogen preparations (cream, tablet, ring) were all superior to placebo for relieving dryness, dyspareunia, and urinary symptoms, with minimal systemic absorption [8]. The 10-mcg estradiol vaginal tablet (Vagifem/Yuvafem) raises serum estradiol only marginally above the postmenopausal baseline.

Ospemifene (Osphena) 60 mg/day is an oral selective estrogen receptor modulator (SERM) FDA-approved for moderate-to-severe dyspareunia due to vulvovaginal atrophy. It acts as an estrogen agonist on vaginal tissue while showing neutral-to-antagonist activity on breast and endometrium [9].

Prasterone (Intrarosa) 6.5 mg vaginal insert delivers dehydroepiandrosterone (DHEA) intravaginally, converting locally to both estrogen and androgen. A 52-week trial (N=558) demonstrated sustained improvement in the four co-primary endpoints: percentage of parabasal cells, percentage of superficial cells, vaginal pH, and dyspareunia severity [10].

Women taking aromatase inhibitors for breast cancer cannot use vaginal estrogen in some oncology protocols. For these patients, hyaluronic acid vaginal moisturizers and ospemifene (if not contraindicated by the oncologist) are considered alternatives, though the evidence base is smaller.

Drugs That Cause or Worsen Postmenopausal Symptoms

Several medication classes induce or amplify the same symptoms that define postmenopause.

Aromatase inhibitors (letrozole, anastrozole, exemestane) block peripheral conversion of androgens to estrogen, dropping already-low postmenopausal estradiol to near-undetectable levels. The ATAC trial reported that 35.7% of women on anastrozole experienced hot flashes versus 29.4% on tamoxifen, and arthralgia rates reached 35.6% [11]. Joint pain and vaginal dryness are dose-limiting for many patients.

GnRH agonists and antagonists (leuprolide, elagolix, relugolix) create a pharmacologic menopause by suppressing pituitary gonadotropin release. Hot flashes occur in over 75% of women on full-dose leuprolide. Add-back therapy with low-dose norethindrone 5 mg/day reduces but does not eliminate vasomotor symptoms.

Tamoxifen, while treating breast cancer, triggers hot flashes in 40-50% of users due to its mixed estrogen agonist/antagonist profile at the hypothalamus [12].

Antipsychotics (risperidone, paliperidone) raise prolactin, which can suppress gonadal function and worsen bone loss. Long-term use accelerates osteoporosis risk in postmenopausal women already losing bone density.

Abrupt SSRI/SNRI discontinuation can produce rebound vasomotor symptoms. Venlafaxine withdrawal is particularly notorious for hot-flash-like episodes (termed "brain zaps" and flushing) within 48 hours of cessation.

Medroxyprogesterone acetate (Depo-Provera) given as contraception in perimenopause, then discontinued, can unmask immediate vasomotor symptoms as endogenous progesterone withdrawal compounds estrogen decline.

Bone-Protective Drugs in the Postmenopausal Period

Accelerated bone loss (2-3% per year in the first 5-7 postmenopausal years) is a direct consequence of estrogen withdrawal. Pharmacologic intervention is guided by DXA T-scores and FRAX risk calculation.

Bisphosphonates remain first-line. Alendronate 70 mg weekly reduced vertebral fracture risk by 44% in the Fracture Intervention Trial (N=2,027) over 3 years [13]. Zoledronic acid 5 mg IV yearly produced a 70% reduction in vertebral fractures in the HORIZON-PFT trial (N=7,765) over 3 years [14].

Denosumab (Prolia) 60 mg SC every 6 months inhibits RANKL and reduced vertebral fractures by 68% in the FREEDOM trial (N=7,868) over 3 years [15]. A critical caveat: discontinuation triggers rebound bone loss and vertebral fracture clustering within 12-18 months.

Romosozumab (Evenity) 210 mg SC monthly for 12 months is a sclerostin inhibitor approved for postmenopausal women at high fracture risk. The FRAME trial (N=7,180) showed a 73% reduction in new vertebral fractures at 12 months versus placebo [16]. Cardiovascular risk must be weighed. The ARCH trial signaled higher major adverse cardiovascular events versus alendronate (2.5% vs. 1.9%).

Hormone therapy itself protects bone. The WHI demonstrated a 34% reduction in hip fractures with CEE plus medroxyprogesterone, though this is no longer recommended as primary osteoporosis treatment due to the risk-benefit profile in older women [17].

Mood, Sleep, and Cognitive Symptoms: Pharmacologic Options

Insomnia affects 40-60% of postmenopausal women. Low-dose estrogen improves sleep quality by reducing nocturnal vasomotor symptoms, but for women who cannot take hormones, targeted sleep pharmacotherapy is needed.

Suvorexant (Belsomra) 10-20 mg and lemborexant (Dayvigo) 5-10 mg are dual orexin receptor antagonists with demonstrated efficacy in postmenopausal insomnia without the dependence risk of benzodiazepines [18].

Depression risk doubles during the menopausal transition and remains elevated in early postmenopause. The KEEPS trial demonstrated that transdermal estradiol improved mood scores in recently postmenopausal women [19]. For women beyond the treatment window or with contraindications, standard antidepressants (escitalopram, desvenlafaxine) are appropriate.

Cognitive complaints ("brain fog") are common but pharmacologically difficult to address. No drug has FDA approval for menopause-associated cognitive decline. The ELITE trial found that estradiol started within 6 years of menopause did not harm (and trended toward helping) cognitive measures, while initiation after 10+ years showed neutral-to-negative effects [20].

Choosing Between Hormonal and Non-Hormonal Approaches

The decision rests on symptom burden, contraindications, time since menopause, and patient preference. The 2022 Endocrine Society guideline recommends systemic estrogen as first-line for bothersome vasomotor symptoms in women under 60 with no contraindications [4].

Absolute contraindications to systemic estrogen include active breast cancer, history of estrogen-receptor-positive breast cancer, active venous thromboembolism, active liver disease, unexplained vaginal bleeding, and known thrombophilia.

For these women, fezolinetant 45 mg/day offers the closest efficacy to hormones without estrogenic activity. Gabapentin, clonidine, and paroxetine 7.5 mg are second-tier. The clinical priority is matching drug mechanism to the dominant symptom cluster: vasomotor, genitourinary, skeletal, or neuropsychiatric.

Combination approaches are common. A woman might use transdermal estradiol 0.05 mg/day for vasomotor symptoms, vaginal estrogen for GSM, and alendronate for osteoporosis simultaneously. There is no pharmacologic conflict between these therapies.

When to Escalate or Change Therapy

If standard-dose hormone therapy fails to control hot flashes within 8 weeks, confirm adherence, check estradiol levels (target 40-100 pg/mL for symptom control), and consider dose adjustment. Switching from oral to transdermal estradiol may improve efficacy in obese women due to bypassing hepatic first-pass metabolism.

If non-hormonal therapy fails after 8-12 weeks, switching drug class rather than escalating dose is preferred. A woman who does not respond to fezolinetant may respond to oxybutynin or gabapentin, since these act on different pathways.

Persistent vaginal symptoms despite low-dose vaginal estrogen should prompt evaluation for lichen sclerosus, vulvar dermatoses, or pelvic floor dysfunction rather than reflexive dose escalation.

Bone-protective therapy requires duration planning. Bisphosphonate holidays after 5 years of oral or 3 years of IV therapy are standard for moderate-risk patients (T-score above −2.5 at the time of holiday). High-risk patients (prior vertebral fracture, T-score ≤ −3.0) typically continue treatment.

Drug Interactions Relevant to Postmenopause Pharmacotherapy

Tamoxifen and strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) should not be combined. Paroxetine reduces the conversion of tamoxifen to its active metabolite endoxifen by approximately 64% [21]. Women on tamoxifen who need SSRI therapy for hot flashes or depression should use venlafaxine, citalopram, or escitalopram instead.

Oral estrogen increases sex hormone-binding globulin (SHBG) and clotting factors via hepatic first-pass effect. Transdermal estradiol avoids this and does not raise VTE risk in observational data [22]. Women on anticoagulants or with thrombotic history should use transdermal formulations exclusively.

Calcium supplements reduce bisphosphonate absorption. Alendronate must be taken on an empty stomach with plain water, 30 minutes before any food, beverage, or other medication. Concurrent proton pump inhibitors may theoretically reduce oral bisphosphonate absorption, though clinical fracture data have not confirmed meaningful efficacy loss.

Thyroid hormone and estrogen interact: oral estrogen increases thyroxine-binding globulin, potentially requiring levothyroxine dose adjustment in 20-30% of hypothyroid women starting oral HRT [23]. Transdermal estradiol does not produce this effect.